<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03475225</url>
  </required_header>
  <id_info>
    <org_study_id>D16-P15</org_study_id>
    <nct_id>NCT03475225</nct_id>
  </id_info>
  <brief_title>Vitamine D in Drug Resistant Epilepsy</brief_title>
  <acronym>EPI-D</acronym>
  <official_title>Effect of the Treatment of Vitamin D Deficiency in Drug-resistant Epilepsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier St Anne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>APHP</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>FFRE</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>LFCE</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier St Anne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Almost all patients with epilepsy living in the region of Paris have vitamin D deficiency,
      which is severe in 1/3 of the cases. The impact of this deficiency on epilepsy is unknown,
      despite the suggested benefits of vitamin D therapy including better seizure control and
      improvement of comorbidities (fatigue, anxiety, depression) in drug-resistant patients.
      Recommendations for vitamin D supplementation based on the serum level in the general
      population cannot be applied to patients with epilepsy due to interference of antiepileptic
      drugs in the vitamin D metabolism. Animal models, mechanisms of action studies and ecological
      information provide objective data for a direct antiepileptic effect of vitamin D. Human
      studies seem to confirm the antiepileptic effect of vitamin D but there are no controlled
      studies on large populations. The investigators aim to assess prospectively the effect of the
      treatment of vitamin D deficiency providing a high level of evidence. The investigators
      propose a multicentre placebo controlled randomized double-blind study, testing vitamin D
      supplementation against placebo in 400 drug-resistant patients to assess the short-term (3
      months) and long-term (1 year) benefits on epilepsy. The investigators hypothesize that the
      treatment of vitamin D deficiency will result in significant reduction of seizure frequency,
      and improvement of comorbid symptoms as well as quality of life. The impact on the care of
      patients is important because better epilepsy control allows reduction of the antiepileptic
      drugs and side effects. This again is a key for the recovery of social and professional
      activities, and reduction of costs related to the disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of this study is to establish the effect of the compensation of vitamin D deficiency
      in the treatment of drug-resistant epilepsy with a high level of evidence in a large
      population. For that, the investigator aim to perform a controlled multicentre prospective
      double-blind randomized study in 400 patients.

      Experimental design

      After a reference period for the collection of clinical data and seizure frequency, all
      eligible patients will undergo biological analyses including serum vitamin D levels, calcium,
      creatinine and albumin. In case of proven deficiency (25(OH)D &lt;30ng/mL), patients will be
      randomized into two arms:

      Experimental group: drug-resistant epileptic patients supplemented with vitamin D. The
      vitamin D administered corresponds to the scheme described below. Control group:
      drug-resistant epileptic patients supplemented with placebo, administered placebo dose is
      equal to therapeutic dosing scheme of vitamin D. Randomization will be centralized and
      stratified by center (considering local disparities) and according to the results of serum
      level, retaining the threshold of 10ng/mL to define severe deficiency, 20 ng/mL for moderate
      deficiency and 30 ng/mL for slight deficiency of vitamin D.

      The drug evaluated is vitamin D3 (cholecalciferol), administered in the form of oral solution
      (2 mL) containing 100,000 IU, manufactured by the laboratory CRINEX and marketed under the
      name UVEDOSE®. The therapeutic indication is the treatment and/or prophylaxis of vitamin D
      deficiency. The usual supplementation in adult is 1 to 2 doses per month depending on the
      severity of the deficiency, the maintenance ranging from 1 dose every month or every 2 to 3
      months.

      Administration in the experimental group and control group The supplementation scheme is
      based on the usual recommendations but does not take into account the severity of the initial
      deficiency, that would be impossible to implement in the context of a double-blind study
      (with in particular the need to adapt each placebo dose in the control group, risking the
      feasibility study). To address this potential bias, the investigators choice a
      supplementation scheme corresponding to a moderate deficiency (25(OH)D &gt;10 and &lt;20ng/mL)
      considering that this is the most common in clinical practice and there is no risk of
      overdose for 25(OH)D level between 20 and 30ng/mL.

      The dosing schedule is as follows:

      UVEDOSE: 1 dose of 100,000 IU every 15 days for 2 months, then 100,000 IU the 3rd month (5
      doses during the first 3 months). Dosage of 25(OH)D will be conducted at 3 and 6 months in
      order to verify the compensation of the initial deficiency and to avoid the risk of overdose.
      Monitoring of serum calcium, albumin and creatinine will be performed at the same time.
      Maintenance therapy in the treatment group will be set at 100,000 IU per month for 6 months
      (11 doses for 12 months followup). After the blind period, the same will be applied to the
      control group (5 doses in 3 months and 1 dose per month for 3 months, 8 doses for 12 months
      follow-up).

      Apart from an overdose, no side effects are expected. An overdose of vitamin D may be
      suspected in case of occurrence of one or more of the following signs: headache, asthenia,
      anorexia, weight loss; nausea, vomiting; polyuria, polydipsia, dehydration; high blood
      pressure; calcium lithiasis; renal insufficiency. Biological signs reflecting the vitamin D
      overdose are hypercalcemia with hypercalciuria. Serum levels of 25(OH)D from 100 to 150 ng/mL
      are exceptionally accompanied by hypercalcemia. High risk of hypercalcemia with clinical
      consequences are reported for levels around 250ng/mL whereas no toxic effects are described
      for serum levels &lt;150 ng/mL. To avoid any risk, the supplementation will be stopped if the
      dosage of 25(OH)D is &gt;100ng/mL and/or serum calcium levels &gt;2.70mmol/l; if the serum calcium
      is &gt;2.60 and &lt;2.70mmol/l, a control will be done and the treatment stopped if &gt;2.60mmol/L.
      Vitamine D treatment will be stopped also if creatinine is &gt;200μmol/L. Vitamin D causes no
      known drug interactions. However its metabolism is accelerated when combined with
      enzyme-inducing drugs, including antiepileptic drugs.

      The entire treatment will be provided to each patient using a kit of 5 doses of UVEDOSE after
      randomization in the experimental group and the unblinding in the control group according to
      the protocol established. The treatment scheme will be clearly explained and dates of
      treatment indicated on the attached schedule. Maintenance therapy will be provided on the
      same terms.

      Patients will note on this calendar the effective date of each dose and bring empty
      containers during the visit at 3 months, 6 months and 12 months. The labeling will be
      performed by the laboratory CRINEX, the kits will be delivered to pharmacy centers. The
      pharmacy of each participating center will handle the management of returns and the
      destruction of processing units. Patients in the control group will receive placebo of
      vitamin D in the same manner as experimental patients.

      The study entails a screening-visit followed by a 3 months reference period, an inclusion
      visit followed by randomization, two follow-up visits (3 and 6 months) and an end-study visit
      at 12 months. The duration of study for each patient is 12 months following the 3 months
      reference-phase. The double-blind phase is between the randomization (V1) and the 3 month
      visit (V2), followed by a 9 month open phase for the 2 groups Eventually, all patients with a
      vitamin D deficiency will be compensated with a 3-month higher dose treatment phase and a
      6-month maintenance phase for the experimental group. The control group will receive the
      placebo for 3 months, then a vitamin D treatment including a 3-month higher dose and a 3
      month maintenance phase.

      The duration of the inclusions is scheduled for 12 months, for research duration of 24
      months. All eligible patients who meet ILAE (International League Against Epilepsy) criteria
      of drug-resistance and inclusion criteria will be informed of the opportunity to participate
      in this research. If accepted, the participants will be asked to fill out a precise seizure
      diary for 3 months before their inclusion in the study (V0). The antiepileptic treatment
      should not be changed during the reference period. The patient cannot receive vitamin D
      during this period.

      Inclusion visit (V1):

      After obtaining informed consent and verification of inclusion criteria, seizure frequency is
      noted and determination of serum 25(OH)D level is done. The vitamin D serum concentration is
      determined with the same technic in each center (immunoluminometric CLIA (Chemiluminescence
      Immunoassay Analyzer) - Liaison XL). The concentration serum calcium, albumin and creatinine
      is determined at the biochemistry laboratory of the participating center. The
      self-questionnaires (Fatigue impact scale : FIS, Hospital anxiety depression scale :HAD,
      Quality of life in epilepsy : QOLIE 31) are completed and handed to the investigator.
      Clinical and demographic data are collected on the case report. After receipt of 25(OH)D
      level results, patients in whom deficiency is objectified (25(OH)D &lt;30ng/mL) are randomized
      between control and experimental group. It is expected 10% of non-deficient patients who are
      not randomized and followed out of the protocol. Treatment appropriate to the protocol for
      each group (vitamin D or placebo) is delivered by the center pharmacy. The results of biology
      (serum calcium, albumin, creatinine) are first referred to the investigator, the treatment
      being delivered in absence of contra-indication (see above).

      3 month-visit (V2): Clinical examination, seizure frequency, determination of 25(OH)D levels,
      serum calcium, albumin, creatinine) and scales (FIS, HAD, QOLIE 31); monitoring of compliance
      (ratio of packaging and check-up of dates); lifting of the blinding phase. Introduction of
      vitamin D supplementation in the placebo group according to the initial plan, pursuit of
      vitamin D supplementation in the experimental group, stop if the serum level is&gt;100 ng/mL
      and/or serum calcium&gt;2.70mmol/L and/or creatinine&gt;200 μmol/L. Control of serum calcium if
      between 2.60 and 2.70 mmol/L, stop if&gt; 2.60 mmol/L.

      6 month-visit (V3): similar to V2, maintenance supplementation in the 2 groups: 1 dose per
      month for 3 months, except if biological contraindication.

      End-study visit (V4, 12 months) similar to V1-V2, vitamin D trial stop. In case of
      deterioration of the clinical situation requiring modification of the antiepileptic treatment
      (excluding one-time treatment with benzodiazepines), the patient will be considered
      not-responder but will not be excluded from the study. The seizure frequency in this case for
      the primary judgment criterion will be the one before the treatment change (LOCF method).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2018</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double blind</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Double blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage reduction of the seizure frequency</measure>
    <time_frame>After 3 months of treatment of vitamin D deficiency</time_frame>
    <description>With respect to the reference period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect on Fatigue scores : Modified Fatigue Impact Scale (M-FIS)</measure>
    <time_frame>3, 6 and 12 months</time_frame>
    <description>Total score at baseline and after Vitamin D treatment (range 0-200; higher values=worse outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect anxiety-depression : Hospital anxiety depression scale (HAD)</measure>
    <time_frame>3, 6 and 12 months</time_frame>
    <description>Total score at baseline and after Vitamin D treatment (range 0-42; higher values=worse outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life in Epilepsy: (QOLIE 31) including 7 subscores: global score calculated on the basis on the mean of each subscore</measure>
    <time_frame>3, 6 and 12 months</time_frame>
    <description>Global score at baseline and after Vitamin D treatment (the higher score, the better outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between serum vitamin D levels and seizure frequency reduction after vitamin D treatment</measure>
    <time_frame>3, 6 and 12 months</time_frame>
    <description>Vitamin D levels and percentage reduction in the seizure frequency compared to the reference period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between serum vitamin D levels and seizure frequency reduction after vitamin D treatment</measure>
    <time_frame>3, 6 and 12 months.</time_frame>
    <description>Vitamin D level and type of AED (enzyme inducer versus non enzyme inducer drugs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between serum vitamin D level and the type and dosage of antiepileptic drugs (AED)</measure>
    <time_frame>Baseline</time_frame>
    <description>Vitamin D level and dose of AED (low dose versus high dose of enzyme inducer drugs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder rate</measure>
    <time_frame>3, 6 and 12 months.</time_frame>
    <description>Responder rate after Vitamin D treatment. Percentage of patients having a reduction of at least 50% of the seizure frequency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission rate after Vitamin D treatment</measure>
    <time_frame>3, 6 and 12 months.]</time_frame>
    <description>Percentage of patients without any seizure (seizure freedom)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Vitamin D according to epilepsy type</measure>
    <time_frame>3, 6 and 12 months</time_frame>
    <description>Responder rate in focal and generalized epilepsy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Vitamin D according to epilepsy severity</measure>
    <time_frame>3, 6 and 12 months</time_frame>
    <description>Percentage of reduction of secondary generalized seizures and epileptic falls in respect to the reference period</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Drug Resistant Epilepsy</condition>
  <arm_group>
    <arm_group_label>Experimental Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug resistant epilepsy patients with proved Vitamin D deficiency (Serum vitamin D level &lt;30ng/ml) Cholecalciferol. 5 doses of cholecalciferol (100 000 IU) in 3 months than 1 dose of cholecalciferol (100 000 IU) per month during 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug resistant epilepsy patients with proved Vitamin D deficiency (Serum vitamin D level&lt;30ng/ml) Placebo than cholecalciferol. 5 doses of placebo in 3 months than 5 doses of cholecalciferol (100 000 IU) in 3 months than 1 dose of cholecalciferol (100 000 IU) per month during 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholecalciferol</intervention_name>
    <description>Cholecalciferol delivery</description>
    <arm_group_label>Experimental Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral</intervention_name>
    <description>manufactured to mimic Cholecalciferol</description>
    <arm_group_label>Control Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age&gt; 15 years

          -  Drug-resistant epilepsy (see definition above)

          -  Having at least 6 unprovoked seizures in the previous 3 months

          -  Epilepsy syndrome unequivocally established

          -  Ability to reliably quantify the seizure frequency

          -  Antiepileptic treatment stable for 3 months prior to inclusion

          -  No vitamin D treatment in the 6 months prior to inclusion vitamin D supplemental diet

          -  Medication compliance (confirmed by plasma levels if available)

          -  Agreeing to participate in the study

          -  Having a social insurance

          -  Parental agreement if patient below the age to be able to give consent (or guardian if
             protected adult)

        Exclusion Criteria:

          -  Progressive brain pathology

          -  Status epilepticus in the 2 years prior to inclusion,

          -  epilepsy surgery planned in the current year

          -  Pregnancy or breast-feeding

          -  Treatments influencing the metabolism of vitamin D other than anticoagulants
             (rifamycin, isoniazid, ketoconazole, 5-FU fluorouracil), leucovorin)

          -  Known hypersensitivity to vitamin D, patients with a history of granulomatosis
             (especially sarcoidosis)

          -  Contraindication to treatment with Uvedose referring to the summary of product
             characteristics

          -  Current or past hypercalcemia or situations accompanied by increased vulnerability to
             hypercalcemia as arrhythmia or digitalis therapy, subjects with calcium lithiasis

          -  Moderate renal impairment with creatinine clearance &lt;60 mL/mn assessed by MDRD
             (Modification of Diet in Renal Disease)

          -  Participation in other studies of other experimental drugs within 30 days before
             enrollment in the study

          -  Abuse of alcohol or drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>CHASSOUX Francine, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Sainte-Anne - 1, rue Cabanis 75014 Paris FRANCE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>CHASSOUX Francine, MD</last_name>
    <phone>145658226</phone>
    <phone_ext>+33</phone_ext>
    <email>f.chassoux@ch-sainte-anne.fr</email>
  </overall_contact>
  <reference>
    <citation>Baxendale S. Seeing the light? Seizures and sunlight. Epilepsy Res. 2009 Mar;84(1):72-6. doi: 10.1016/j.eplepsyres.2008.11.015. Epub 2009 Jan 13.</citation>
    <PMID>19144500</PMID>
  </reference>
  <reference>
    <citation>Beyenburg S, Stavem K, Schmidt D. Placebo-corrected efficacy of modern antiepileptic drugs for refractory epilepsy: systematic review and meta-analysis. Epilepsia. 2010 Jan;51(1):7-26. doi: 10.1111/j.1528-1167.2009.02299.x. Epub 2009 Sep 10. Review.</citation>
    <PMID>19744114</PMID>
  </reference>
  <reference>
    <citation>Borowicz KK, Morawska M, Furmanek-Karwowska K, Luszczki JJ, Czuczwar SJ. Cholecalciferol enhances the anticonvulsant effect of conventional antiepileptic drugs in the mouse model of maximal electroshock. Eur J Pharmacol. 2007 Nov 14;573(1-3):111-5. Epub 2007 Jul 10.</citation>
    <PMID>17643415</PMID>
  </reference>
  <reference>
    <citation>Callaghan B, Schlesinger M, Rodemer W, Pollard J, Hesdorffer D, Allen Hauser W, French J. Remission and relapse in a drug-resistant epilepsy population followed prospectively. Epilepsia. 2011 Mar;52(3):619-26. doi: 10.1111/j.1528-1167.2010.02929.x. Epub 2011 Jan 26.</citation>
    <PMID>21269287</PMID>
  </reference>
  <reference>
    <citation>Carbone LD, Johnson KC, Robbins J, Larson JC, Curb JD, Watson K, Gass M, Lacroix AZ. Antiepileptic drug use, falls, fractures, and BMD in postmenopausal women: findings from the women's health initiative (WHI). J Bone Miner Res. 2010 Apr;25(4):873-81. doi: 10.1359/jbmr.091027.</citation>
    <PMID>19839772</PMID>
  </reference>
  <reference>
    <citation>Carnes J, Quinn S, Nelson M, Jones G, Winzenberg T. Intermittent high-dose vitamin D corrects vitamin D deficiency in adolescents: a pilot study. Eur J Clin Nutr. 2012 Apr;66(4):530-2. doi: 10.1038/ejcn.2011.204. Epub 2011 Dec 21.</citation>
    <PMID>22190133</PMID>
  </reference>
  <reference>
    <citation>Cavalier E, Faché W, Souberbielle JC. A Randomised, Double-Blinded, Placebo-Controlled, Parallel Study of Vitamin D3 Supplementation with Different Schemes Based on Multiples of 25,000 IU Doses. Int J Endocrinol. 2013;2013:327265. doi: 10.1155/2013/327265. Epub 2013 Jan 28.</citation>
    <PMID>23431293</PMID>
  </reference>
  <reference>
    <citation>Christensen J, Vestergaard M, Mortensen PB, Sidenius P, Agerbo E. Epilepsy and risk of suicide: a population-based case-control study. Lancet Neurol. 2007 Aug;6(8):693-8.</citation>
    <PMID>17611160</PMID>
  </reference>
  <reference>
    <citation>Christiansen C, Rodbro P, Sjö O. &quot;Anticonvulsant action&quot; of vitamin D in epileptic patients? A controlled pilot study. Br Med J. 1974 May 4;2(5913):258-9.</citation>
    <PMID>4207965</PMID>
  </reference>
  <reference>
    <citation>Devaux B, Chassoux F, Guenot M, Haegelen C, Bartolomei F, Rougier A, Bourgeois M, Colnat-Coulbois S, Bulteau C, Sol JC, Kherli P, Geffredo S, Reyns N, Vinchon M, Proust F, Masnou P, Dupont S, Chabardes S, Coubes P. [Epilepsy surgery in France]. Neurochirurgie. 2008 May;54(3):453-65. doi: 10.1016/j.neuchi.2008.02.041. Epub 2008 May 7. French.</citation>
    <PMID>18466930</PMID>
  </reference>
  <reference>
    <citation>Duhamel JF, Zeghoud F, Sempé M, Boudailliez B, Odièvre M, Laurans M, Garabédian M, Mallet E. [Prevention of vitamin D deficiency in adolescents and pre-adolescents. An interventional multicenter study on the biological effect of repeated doses of 100,000 IU of vitamin D3]. Arch Pediatr. 2000 Feb;7(2):148-53. French.</citation>
    <PMID>10701059</PMID>
  </reference>
  <reference>
    <citation>Duncan JS, Sander JW, Sisodiya SM, Walker MC. Adult epilepsy. Lancet. 2006 Apr 1;367(9516):1087-100. Review.</citation>
    <PMID>16581409</PMID>
  </reference>
  <reference>
    <citation>Eyles DW, Smith S, Kinobe R, Hewison M, McGrath JJ. Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. J Chem Neuroanat. 2005 Jan;29(1):21-30.</citation>
    <PMID>15589699</PMID>
  </reference>
  <reference>
    <citation>Fazel S, Wolf A, Långström N, Newton CR, Lichtenstein P. Premature mortality in epilepsy and the role of psychiatric comorbidity: a total population study. Lancet. 2013 Nov 16;382(9905):1646-54. doi: 10.1016/S0140-6736(13)60899-5. Epub 2013 Jul 22.</citation>
    <PMID>23883699</PMID>
  </reference>
  <reference>
    <citation>Fertig E, Fureman BE, Bergey GK, Brodie MA, Hesdorffer DC, Hirtz D, Kossoff EH, LaFrance WC Jr, Versavel M, French J; National Institute of Neurological Disorders and Stroke. Inclusion and exclusion criteria for epilepsy clinical trials-recommendations from the April 30, 2011 NINDS workshop. Epilepsy Res. 2014 Jul;108(5):825-32. doi: 10.1016/j.eplepsyres.2014.02.011. Epub 2014 Mar 1.</citation>
    <PMID>24702822</PMID>
  </reference>
  <reference>
    <citation>Hamelin S, Kahane P, Vercueil L. Fatigue in epilepsy: a prospective inter-ictal and post-ictal survey. Epilepsy Res. 2010 Oct;91(2-3):153-60. doi: 10.1016/j.eplepsyres.2010.07.006. Epub 2010 Aug 12.</citation>
    <PMID>20708384</PMID>
  </reference>
  <reference>
    <citation>Hermann BP, Seidenberg M, Dow C, Jones J, Rutecki P, Bhattacharya A, Bell B. Cognitive prognosis in chronic temporal lobe epilepsy. Ann Neurol. 2006 Jul;60(1):80-7.</citation>
    <PMID>16802302</PMID>
  </reference>
  <reference>
    <citation>Hesdorffer DC. Motor vehicle accidents, suicides, and assaults in epilepsy: a population-based study. Neurology. 2011 Oct 25;77(17):1653; author reply 1653-4. doi: 10.1212/WNL.0b013e318230b17e.</citation>
    <PMID>22025462</PMID>
  </reference>
  <reference>
    <citation>Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM; Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011 Jul;96(7):1911-30. doi: 10.1210/jc.2011-0385. Epub 2011 Jun 6. Erratum in: J Clin Endocrinol Metab. 2011 Dec;96(12):3908.</citation>
    <PMID>21646368</PMID>
  </reference>
  <reference>
    <citation>Holló A, Clemens Z, Kamondi A, Lakatos P, Szűcs A. Correction of vitamin D deficiency improves seizure control in epilepsy: a pilot study. Epilepsy Behav. 2012 May;24(1):131-3. doi: 10.1016/j.yebeh.2012.03.011. Epub 2012 Apr 11.</citation>
    <PMID>22503468</PMID>
  </reference>
  <reference>
    <citation>Holló A, Clemens Z, Lakatos P. Epilepsy and vitamin D. Int J Neurosci. 2014 Jun;124(6):387-93. doi: 10.3109/00207454.2013.847836. Epub 2013 Nov 7. Review.</citation>
    <PMID>24063762</PMID>
  </reference>
  <reference>
    <citation>Kalueff AV, Minasyan A, Tuohimaa P. Anticonvulsant effects of 1,25-dihydroxyvitamin D in chemically induced seizures in mice. Brain Res Bull. 2005 Sep 30;67(1-2):156-60.</citation>
    <PMID>16140175</PMID>
  </reference>
  <reference>
    <citation>Kalueff AV, Minasyan A, Keisala T, Kuuslahti M, Miettinen S, Tuohimaa P. Increased severity of chemically induced seizures in mice with partially deleted Vitamin D receptor gene. Neurosci Lett. 2006 Feb 6;394(1):69-73. Epub 2005 Oct 25.</citation>
    <PMID>16256271</PMID>
  </reference>
  <reference>
    <citation>Kanner AM. Depression in epilepsy: prevalence, clinical semiology, pathogenic mechanisms, and treatment. Biol Psychiatry. 2003 Aug 1;54(3):388-98. Review.</citation>
    <PMID>12893113</PMID>
  </reference>
  <reference>
    <citation>Kanner AM. The treatment of depressive disorders in epilepsy: what all neurologists should know. Epilepsia. 2013 Mar;54 Suppl 1:3-12. doi: 10.1111/epi.12100. Review.</citation>
    <PMID>23458461</PMID>
  </reference>
  <reference>
    <citation>Kanner AM. Do psychiatric comorbidities have a negative impact on the course and treatment of seizure disorders? Curr Opin Neurol. 2013 Apr;26(2):208-13. doi: 10.1097/WCO.0b013e32835ee579. Review.</citation>
    <PMID>23429545</PMID>
  </reference>
  <reference>
    <citation>Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000 Feb 3;342(5):314-9.</citation>
    <PMID>10660394</PMID>
  </reference>
  <reference>
    <citation>Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, Moshé SL, Perucca E, Wiebe S, French J. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010 Jun;51(6):1069-77. doi: 10.1111/j.1528-1167.2009.02397.x. Epub 2009 Nov 3. Erratum in: Epilepsia. 2010 Sep;51(9):1922.</citation>
    <PMID>19889013</PMID>
  </reference>
  <reference>
    <citation>Kwan P, Schachter SC, Brodie MJ. Drug-resistant epilepsy. N Engl J Med. 2011 Sep 8;365(10):919-26. doi: 10.1056/NEJMra1004418. Review.</citation>
    <PMID>21899452</PMID>
  </reference>
  <reference>
    <citation>Lazzari AA, Dussault PM, Thakore-James M, Gagnon D, Baker E, Davis SA, Houranieh AM. Prevention of bone loss and vertebral fractures in patients with chronic epilepsy--antiepileptic drug and osteoporosis prevention trial. Epilepsia. 2013 Nov;54(11):1997-2004. doi: 10.1111/epi.12351. Epub 2013 Sep 6.</citation>
    <PMID>24010637</PMID>
  </reference>
  <reference>
    <citation>Mann MW, Pons G. [Drug resistance in partial epilepsy: epidemiology, mechanisms, pharmacogenetics and therapeutical aspects]. Neurochirurgie. 2008 May;54(3):259-64. doi: 10.1016/j.neuchi.2008.02.018. Epub 2008 Apr 15. Review. French.</citation>
    <PMID>18417170</PMID>
  </reference>
  <reference>
    <citation>Menon B, Harinarayan CV. The effect of anti epileptic drug therapy on serum 25-hydroxyvitamin D and parameters of calcium and bone metabolism--a longitudinal study. Seizure. 2010 Apr;19(3):153-8. doi: 10.1016/j.seizure.2010.01.006. Epub 2010 Feb 7.</citation>
    <PMID>20144552</PMID>
  </reference>
  <reference>
    <citation>McGrath J, Feron F, Eyles D, Mackay-Sim A. Vitamin D: the neglected neurosteroid? Trends Neurosci. 2001 Oct;24(10):570-2.</citation>
    <PMID>11576669</PMID>
  </reference>
  <reference>
    <citation>Picot MC, Jaussent A, Neveu D, Kahane P, Crespel A, Gelisse P, Hirsch E, Derambure P, Dupont S, Landré E, Chassoux F, Valton L, Vignal JP, Marchal C, Lamy C, Semah F, Biraben A, Arzimanoglou A, Petit J, Thomas P, Macioce V, Dujols P, Ryvlin P. Cost-effectiveness analysis of epilepsy surgery in a controlled cohort of adult patients with intractable partial epilepsy: A 5-year follow-up study. Epilepsia. 2016 Oct;57(10):1669-1679. doi: 10.1111/epi.13492. Epub 2016 Sep 5.</citation>
    <PMID>27595433</PMID>
  </reference>
  <reference>
    <citation>Pierrot-Deseilligny C, Souberbielle JC. Is hypovitaminosis D one of the environmental risk factors for multiple sclerosis? Brain. 2010 Jul;133(Pt 7):1869-88. doi: 10.1093/brain/awq147. Review.</citation>
    <PMID>20584945</PMID>
  </reference>
  <reference>
    <citation>Pierrot-Deseilligny C, Souberbielle JC. Widespread vitamin D insufficiency: A new challenge for primary prevention, with particular reference to multiple sclerosis. Presse Med. 2011 Apr;40(4 Pt 1):349-56. doi: 10.1016/j.lpm.2011.01.003. Epub 2011 Feb 17. Review.</citation>
    <PMID>21333483</PMID>
  </reference>
  <reference>
    <citation>Procopio M, Marriott PK, Williams P. Season of birth: aetiological implications for epilepsy. Seizure. 1997 Apr;6(2):99-105.</citation>
    <PMID>9153721</PMID>
  </reference>
  <reference>
    <citation>Saggese G, Vierucci F, Boot AM, Czech-Kowalska J, Weber G, Camargo CA Jr, Mallet E, Fanos M, Shaw NJ, Holick MF. Vitamin D in childhood and adolescence: an expert position statement. Eur J Pediatr. 2015 May;174(5):565-76. doi: 10.1007/s00431-015-2524-6. Epub 2015 Apr 2. Review.</citation>
    <PMID>25833762</PMID>
  </reference>
  <reference>
    <citation>Schiller Y, Najjar Y. Quantifying the response to antiepileptic drugs: effect of past treatment history. Neurology. 2008 Jan 1;70(1):54-65. doi: 10.1212/01.wnl.0000286959.22040.6e.</citation>
    <PMID>18166707</PMID>
  </reference>
  <reference>
    <citation>Schmidt D, Schachter SC. Drug treatment of epilepsy in adults. BMJ. 2014 Feb 28;348:g254. doi: 10.1136/bmj.g254. Review.</citation>
    <PMID>24583319</PMID>
  </reference>
  <reference>
    <citation>Semah F, Picot MC, Adam C, Broglin D, Arzimanoglou A, Bazin B, Cavalcanti D, Baulac M. Is the underlying cause of epilepsy a major prognostic factor for recurrence? Neurology. 1998 Nov;51(5):1256-62.</citation>
    <PMID>9818842</PMID>
  </reference>
  <reference>
    <citation>Siegel A, Malkowitz L, Moskovits MJ, Christakos S. Administration of 1,25-dihydroxyvitamin D3 results in the elevation of hippocampal seizure threshold levels in rats. Brain Res. 1984 Apr 23;298(1):125-9.</citation>
    <PMID>6547070</PMID>
  </reference>
  <reference>
    <citation>Sisodiya SM, Lin WR, Harding BN, Squier MV, Thom M. Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. Brain. 2002 Jan;125(Pt 1):22-31.</citation>
    <PMID>11834590</PMID>
  </reference>
  <reference>
    <citation>Souberbielle JC, Benhamou CL, Cortet B, Rousière M, Roux C, Abitbol V, Audran M, Bachetta J, Beauchet O, Blain H, Breuil V, Briot K, Brunet P, Chanson P, Cormier C, Courbebaisse M, Fardellone P, Fouque D, Friedlander G, Gauvain JB, Groussin L, Houillier P, Jacot W, Jean G, Kamenicky P, Lafage-Proust MH, Legrand E, Levy-Weil F, Linglart A, Mallet E, Marcelli C, Maruani G, Montagnon F, Personne V, Prié D, Raynaud-Simon A, Rolland Y, Salle B, Sault C, Schott AM, Thervet E, Urena-Torres P, Viard JP, Weryha G, Pierrot-Deseilligny C, Young J, Thomas T. [HAS report on vitamin D measurement: don't go from an extreme situation to another as extreme situation]. Presse Med. 2014 Jan;43(1):5-8. doi: 10.1016/j.lpm.2013.12.005. French.</citation>
    <PMID>24439118</PMID>
  </reference>
  <reference>
    <citation>Steinhoff BJ. Efficacy of perampanel: a review of pooled data. Epilepsia. 2014 Jan;55 Suppl 1:9-12. doi: 10.1111/epi.12493. Review.</citation>
    <PMID>24400691</PMID>
  </reference>
  <reference>
    <citation>Teagarden DL, Meador KJ, Loring DW. Low vitamin D levels are common in patients with epilepsy. Epilepsy Res. 2014 Oct;108(8):1352-6. doi: 10.1016/j.eplepsyres.2014.06.008. Epub 2014 Jul 6.</citation>
    <PMID>25060996</PMID>
  </reference>
  <reference>
    <citation>Tellez-Zenteno JF, Patten SB, Jetté N, Williams J, Wiebe S. Psychiatric comorbidity in epilepsy: a population-based analysis. Epilepsia. 2007 Dec;48(12):2336-44. Epub 2007 Jul 28.</citation>
    <PMID>17662062</PMID>
  </reference>
  <reference>
    <citation>Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with use of antiepileptic drugs. Epilepsia. 2004 Nov;45(11):1330-7.</citation>
    <PMID>15509233</PMID>
  </reference>
  <reference>
    <citation>Vidailhet M, Mallet E, Bocquet A, Bresson JL, Briend A, Chouraqui JP, Darmaun D, Dupont C, Frelut ML, Ghisolfi J, Girardet JP, Goulet O, Hankard R, Rieu D, Simeoni U, Turck D; Comité de nutrition de la Société française de pédiatrie. Vitamin D: still a topical matter in children and adolescents. A position paper by the Committee on Nutrition of the French Society of Paediatrics. Arch Pediatr. 2012 Mar;19(3):316-28. doi: 10.1016/j.arcped.2011.12.015. Epub 2012 Jan 27.</citation>
    <PMID>22284232</PMID>
  </reference>
  <reference>
    <citation>Wassenaar M, Leijten FS, Egberts TC, Moons KG, Uijl SG. Prognostic factors for medically intractable epilepsy: a systematic review. Epilepsy Res. 2013 Oct;106(3):301-10. doi: 10.1016/j.eplepsyres.2013.06.013. Epub 2013 Jul 20. Review.</citation>
    <PMID>23880113</PMID>
  </reference>
  <reference>
    <citation>de Zélicourt M, de Toffol B, Vespignani H, Laurendeau C, Lévy-Bachelot L, Murat C, Fagnani F. Management of focal epilepsy in adults treated with polytherapy in France: the direct cost of drug resistance (ESPERA study). Seizure. 2014 May;23(5):349-56. doi: 10.1016/j.seizure.2014.01.016. Epub 2014 Jan 30.</citation>
    <PMID>24560531</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 26, 2017</study_first_submitted>
  <study_first_submitted_qc>March 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2018</study_first_posted>
  <last_update_submitted>April 12, 2018</last_update_submitted>
  <last_update_submitted_qc>April 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Epilepsy</keyword>
  <keyword>Drug-resistance</keyword>
  <keyword>Vitamin D deficiency</keyword>
  <keyword>Metabolism</keyword>
  <keyword>Controlled study antiepileptic drugs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
    <mesh_term>Drug Resistant Epilepsy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

